Ocean Biomedical (OCEA) announces new findings in relation to treatment options for Hermansky-Pudlak Syndrome
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) announced its commitment to developing viable treatment options for Hermansky-Pudlak Syndrome (HPS) on Thursday. The company disclosed its plans to target OCF-203, its […]
The post Ocean Biomedical (OCEA) announces new findings in relation to treatment options for Hermansky-Pudlak Syndrome first appeared on AlphaStreet.